Understanding Advanced Prostate Cancer

/Understanding Advanced Prostate Cancer

Kegel Smegal

By Steven Lavender https://theptpractice.nyc By now many of you would have heard the word Kegel.  Arnold Kegel was an American gynecologist who developed exercises to strengthen “relaxed genitals” in females.  The exercises have been well studied and are now taught to both men and women as the first line of defense against incontinence both urinary and [...]

By |2019-04-16T16:02:27-04:00April 16th, 2019|Understanding Advanced Prostate Cancer|0 Comments

Malecare – 20 Year Celebration in NYC

Celebrate 20 years of Malecare Prostate Cancer Support Groups., at a special two hour discussion with three of NYC"s top cancer doctors. Your questions will be welcome! Dr. Kelly Cassano, Senior Associate Dean for Clinical Affairs, Chief of Ambulatory Care at Mount Sinai Downtown William K. Oh, MD, Medical Oncologist and Robert Stewart, MD, Radiation [...]

By |2018-09-20T11:58:32-04:00September 20th, 2018|Understanding Advanced Prostate Cancer|0 Comments

XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone.  It will be a [...]

A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer

Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs.   We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity [...]

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM [...]